person · Reporting owner
Xanthopoulos Kleanthis Gabriel
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Connect Biopharma Holdings LtdCNTB · Entity 6516 | Director | September 30, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Connect Biopharma Holdings Ltd
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 91,554 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 5,000 · Balance 91,554 F1: In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation for his 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Dr. Xanthopoulos for his service as a director during the third quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding September 30, 2026, rounded down to the nearest whole share. |
Filing footnotes · ownership attribution and instrument terms
F1: In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation for his 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Dr. Xanthopoulos for his service as a director during the third quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding September 30, 2026, rounded down to the nearest whole share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 2, 2026 01:18 UTC | Connect Biopharma Holdings Ltd CNTB · Entity 6516 | GrantOrdinary Shares | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002115875-26-000007 · wk-form4_1790889535.xml · nonDerivative · entry 1 Xanthopoulos Kleanthis Gabriel · CIK 0002115875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,554 F1 · shares: In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation for his 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Dr. Xanthopoulos for his service as a director during the third quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding September 30, 2026, rounded down to the nearest whole share. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:26 UTC | Connect Biopharma Holdings Ltd CNTB · Entity 6516 | GrantOrdinary Shares | 3,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001835268-26-000022 · wk-form4_1782937615.xml · nonDerivative · entry 1 Xanthopoulos Kleanthis Gabriel · CIK 0002115875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,554 F1 · shares: In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation for his 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Dr. Xanthopoulos for his service as a director during the second quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding June 30, 2026, rounded down to the nearest whole share. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:27 UTC | Connect Biopharma Holdings Ltd CNTB · Entity 6516 | GrantOrdinary Shares | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0002115875-26-000004 · wk-form4_1775161671.xml · nonDerivative · entry 1 Xanthopoulos Kleanthis Gabriel · CIK 0002115875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,816 F1 · shares: In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation for his 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Dr. Xanthopoulos for his service as a director during the first quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares over the 30 consecutive trading days immediately preceding March 31, 2026, rounded down to the nearest whole share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.